BioSenic SA has appointed Carole Nicco as chief scientific officer to help the company build its pipeline of experimental treatments for chronic inflammatory and autoimmune diseases. BioSenic is working with cell and gene therapy technologies and with arsenic trioxide chemotherapy. Dr Nicco has been working as a scientific collaborator with multiple companies, conducting clinical trials with agents targeting inflammation and the immune system. Most recently, she has been a principle investigator at the Cochin Institute, a biomedical research centre affiliated with Inserm in France. She holds a PhD in human physiology and physiopathology from the Denis Diderot University in Paris.
BioSenic announced the appointment on 18 January 2023.
Copyright 2023 Evernow Publishing Ltd